Dr. Reddy's Laboratories Limited (RDY) Stock Price & Analysis
Dr. Reddy's Laboratories Limited (RDY) — MoonshotScore 81/100 (Exceptional band), calculated Oct 4, 2026. Price $12.25 (0.00%), as of the Oct 2, 2026 trading session; market cap $10.2B. Expected results Oct 23, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Dr. Reddy's Laboratories Limited · RDY · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Dr. Reddy's Laboratories (RDY)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, a strong balance sheet and elite growth, with no real weak spot — fairly priced, so not a bargain entry. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Quiet.
- quarterly revenue $843M (Q1 FY2027, quarter ended Jun 2026)
- EPS beat 4 of 8
- Altman Z 5.10 · Piotroski F 5
Helping: business quality, balance-sheet strength, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 80 | Strong | |
| 80 | Strong | |
| 80 | Exceptional | |
| 80 | Exceptional | |
| 82 | Exceptional | |
| 82 | Exceptional |
The score was 81 in the stored Oct 3, 2026 snapshot and remains 81 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Financial Safety -1 and Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $12.25 | |
| Change on the day | 0.00% | |
| 52-week range | $11.36 – $15.67 | |
| Market capitalisation | $10.2B | |
| Price / earnings (trailing) | 30.34 | |
| Shares traded on the day | 3.63M | |
| Beta (volatility vs the S&P 500) | 0.25 | |
| Dividends per share (last 12 months) | $0.08 | |
| Dividend yield (last 12 months) | 0.68% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · in line with the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextCouncil Score · weighted blend of 2 available disciplines
Council score for Dr. Reddy's Laboratories (RDY): Bullish Lean
68/100 · B+Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 14, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 14, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the RDY film — every key number, told as a short cinematic story
~2 min · open the film
What is Dr. Reddy's Laboratories (RDY), and what does it report?
Short answer · as of
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. Dr. Reddy's Laboratories Limited (RDY) is listed on NYSE. Healthcare / Drug Manufacturers Specialty & Generic SEC filing business address: 8-2-337, Road NO.3 Banjara Hills, Hyderabad, 500-034. It employs 27,527 people and is led by Erez Israeli. In Q1 FY2027 it reported revenue of $843M and net income of $46M. The market values it at $10.2B.
What do the latest results show for Dr. Reddy's Laboratories (RDY)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of $843M. Against analyst estimates the company has EPS beat 4 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $835.68M Jul 21, 2026
- Latest report · revenue estimate
- $850.56M Jul 21, 2026
- Latest report · revenue vs estimate
- Below estimate Jul 21, 2026
- Latest report · EPS vs estimate
- Below estimate Jul 21, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 21, 2026 | $835.68M | $850.56M | $0.0600 | $0.0918 |
| May 11, 2026 | $785.89M | $886.57M | $0.0600 | $0.0900 |
| Jan 20, 2026 | $951.64M | $927.68M | $0.1600 | $0.1600 |
| Oct 24, 2025 | $1.00B | $979.76M | $0.1900 | $0.1800 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | $843M | $46M | $0.06 (diluted) |
| Q4 FY2026 | $793M | $23M | $0.03 (diluted) |
| Q3 FY2026 | $906M | $126M | $0.15 (diluted) |
| Q2 FY2026 | $914M | $149M | $0.18 (diluted) |
What are the financial strengths and risks for Dr. Reddy's Laboratories (RDY)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth as strengths. The distress and quality screens read Altman Z 5.10 · Piotroski F 5. Trailing ratios: ROE 8.9% · ROA 5.8% · current ratio 1.90 · earnings yield 3.2% · free-cash-flow yield 1.4%.
What should you watch next at Dr. Reddy's Laboratories (RDY)?
Short answer · as of
The next earnings report is expected on Oct 23, 2026.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Dr. Reddy's Laboratories compare with its peers?
Short answer
Dr. Reddy's Laboratories's score ranks 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $72.18 Oct 2, 2026 | $1.64B | 95 5-pillar Oct 4, 2026 | |
| $99.96 Oct 2, 2026 | $6.51B | 91 5-pillar Oct 4, 2026 | |
| $69.69 Oct 2, 2026 | $29.2B | 87 5-pillar Oct 4, 2026 | |
| Dr. Reddy's Laboratories (RDY) — this page | $12.25 | $10.2B | 81 |
| $8.80 Oct 2, 2026 | $38.8B | 78 5-pillar Oct 4, 2026 | |
| $37.24 Oct 2, 2026 | $1.51B | 74 5-pillar Oct 4, 2026 | |
| $14.20 Oct 2, 2026 | $2.48B | 69 5-pillar Oct 4, 2026 | |
| $20.30 Oct 2, 2026 | $6.48B | 67 5-pillar Oct 4, 2026 | |
| $39.53 Oct 2, 2026 | $46.0B | 66 5-pillar Oct 4, 2026 | |
| $17.86 Oct 2, 2026 | $56.8B | 64 5-pillar Oct 4, 2026 | |
| $35.71 Oct 2, 2026 | $4.46B | 60 5-pillar Oct 4, 2026 | |
| $42.38 Oct 2, 2026 | $2.46B | 55 5-pillar Oct 4, 2026 | |
| $6.82 Oct 2, 2026 | $3.38B | 47 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 15.1% Period end Jun 30, 2026
- Previous quarter · ownership
- 14.4% Prior to period end Jun 30, 2026
- Reporting holders
- 241 Period end Jun 30, 2026
- Previous quarter · holders
- 250 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Robeco Institutional Asset Management B.V. | 18,021,100 |
| Morgan Stanley | 10,936,320 |
| Blackrock, INC. | 10,585,742 |
| Royal Bank Of Canada | 9,213,269 |
| Aikya Investment Management Ltd | 8,493,852 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Dr. Reddy's Laboratories (RDY)?
What Investors Ask About Dr. Reddy's Laboratories (RDY) — Healthcare
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Dr. Reddy’s Global Generics business sell?
Global Generics sells prescription and over-the-counter finished medicines under proprietary brands or as generic equivalents, and it also contains the biologics activity. Its revenue reflects commercial medicine sales rather than ingredient supply or contract research work.
How does Dr. Reddy’s PSAI business differ from Global Generics?
PSAI supplies active ingredients, chemical intermediates, custom ingredients and steroids, while also providing contract research. Global Generics sells finished medicines and biologics, so the divisions serve different stages of pharmaceutical production.
What does the Curis partnership add to Dr. Reddy’s oncology work?
The Curis partnership extends Dr. Reddy’s activity into the discovery, development and commercialization of small-molecule antagonists aimed at immuno-oncology and precision-oncology targets. It sits alongside the company’s broader development work in cancer and inflammatory conditions.
What is the RDY stock price today?
The last price recorded on this page for Dr. Reddy's Laboratories Limited (RDY) is $12.25, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does RDY pay a dividend?
Yes. Dr. Reddy's Laboratories Limited (RDY) shows a trailing 12-month dividend yield of 0.68%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (52 figures)
The 52 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 8-2-337, Road NO.3 Banjara Hills, Hyderabad, 500-034 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "8-2-337, Road No. 3, Hyderabad, TS, 500034, IN". |
FMP — 40 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $12.25 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T12:34:24.147Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $10.2B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:02.000Z. Captured from FMP at 2026-10-04T12:34:22.571Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Oct 23, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q1 FY2027 | $843M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 30.34 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 3.63M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.25 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers Specialty & Generic | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | |
id.employees | Employees | 27,527 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
id.ceo | Chief executive | Erez Israeli | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_income | Net income, Q1 FY2027 | $46M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-07-21.revenue_actual | Revenue · reported — report date 2026-07-21 | $835.68M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-21.revenue_estimated | Revenue · estimate — report date 2026-07-21 | $850.56M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-21.eps_actual | EPS · reported — report date 2026-07-21 | $0.0600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-21.eps_estimated | EPS · estimate — report date 2026-07-21 | $0.0918 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.revenue_actual | Revenue · reported — report date 2026-05-11 | $785.89M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.revenue_estimated | Revenue · estimate — report date 2026-05-11 | $886.57M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.eps_actual | EPS · reported — report date 2026-05-11 | $0.0600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.eps_estimated | EPS · estimate — report date 2026-05-11 | $0.0900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-20.revenue_actual | Revenue · reported — report date 2026-01-20 | $951.64M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-20.revenue_estimated | Revenue · estimate — report date 2026-01-20 | $927.68M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-20.eps_actual | EPS · reported — report date 2026-01-20 | $0.1600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-20.eps_estimated | EPS · estimate — report date 2026-01-20 | $0.1600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-24.revenue_actual | Revenue · reported — report date 2025-10-24 | $1.00B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-24.revenue_estimated | Revenue · estimate — report date 2025-10-24 | $979.76M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-24.eps_actual | EPS · reported — report date 2025-10-24 | $0.1900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-24.eps_estimated | EPS · estimate — report date 2025-10-24 | $0.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2027 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.institutions.depth.ownership_pct | Institutional ownership | 15.1% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 14.4% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 241 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 250 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Robeco Institutional Asset Management B.V. — shares in provider snapshot | 18,021,100 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Morgan Stanley — shares in provider snapshot | 10,936,320 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Blackrock, INC. — shares in provider snapshot | 10,585,742 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Royal Bank Of Canada — shares in provider snapshot | 9,213,269 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Aikya Investment Management Ltd — shares in provider snapshot | 8,493,852 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-25 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 5.10 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
px.range52 | 52-week range | $11.36 – $15.67 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 8.9% · ROA 5.8% · current ratio 1.90 · earnings yield 3.2% · free-cash-flow yield 1.4% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.08 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.68% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-21.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($835.68M) with the recorded estimate ($850.56M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-21.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.0600) with the recorded estimate ($0.0918) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 3 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 81 of 100 · Exceptional · pillars 83 / 73 / 57 / 90 / 55 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 81 (stored snapshot Oct 3, 2026) → 81 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots | |
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-07-21. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-21.revenue_actual,earn.history.depth.2026-07-21.revenue_estimated,earn.history.depth.2026-07-21.revenue_actual.comparison,earn.history.depth.2026-07-21.eps_actual.comparison,earn.history.depth.2026-07-21.eps_actual,earn.history.depth.2026-07-21.eps_estimated,earn.history.depth.2026-05-11.revenue_actual,earn.history.depth.2026-05-11.revenue_estimated,earn.history.depth.2026-05-11.eps_actual,earn.history.depth.2026-05-11.eps_estimated,earn.history.depth.2026-01-20.revenue_actual,earn.history.depth.2026-01-20.revenue_estimated,earn.history.depth.2026-01-20.eps_actual,earn.history.depth.2026-01-20.eps_estimated,earn.history.depth.2025-10-24.revenue_actual,earn.history.depth.2025-10-24.revenue_estimated,earn.history.depth.2025-10-24.eps_actual,earn.history.depth.2025-10-24.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.